Development Of Januvia-Lipitor Combo Ends
Merck & Co. has disclosed that it is ending development of a pill that combines its diabetes drug Januvia with atorvastatin, the main ingredient in Lipitor.
Merck cited unspecified business reasons for ending clinical work on the pill, which was designated MK-0431E. It disclosed the move in a form filed with the Securities and Exchange Commission.
Januvia is the Whitehouse Station, N.J., company's best-selling drug. In the third quarter revenue from Januvia rose 15% to $975 million. That was 50% more revenue than its next biggest product, the cholesterol drug Zetia.
Lipitor is marketed by Pfizer Inc. It was the best-selling drug in history, but lost patent protection about a year ago, allowing generic versions to reach the market.
Date: November 13, 2012
Source: Associated Press